#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Chronic Lymphocytic Leukemia

We recommend hematologie

OHD 2024: What’s New in Data and Experiences from Real Practice with Venetoclax Regimens?

19. 6. 2024 Source: Chronic Lymphocytic Leukemia

How to utilize venetoclax regimens most effectively for treating chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML) in real practice was the topic of a satellite symposium organized by AbbVie during this year’s XXXVIth Olomouc Hematology Days. Three hemato-oncologists shared their experiences with venetoclax treatment, moderated by Prof. MUDr. Tomáš Papajík, CSc., from the Department of Hemato-Oncology, Faculty of Medicine, Palacky University and University Hospital Olomouc.

CLL

Benefits of Time-Limited CLL Therapy

The advent of new targeted molecules has significantly influenced the possibilities of therapy for…
5. 3. 2024 Source: Chronic Lymphocytic Leukemia
červená kniha

Selecting from the Red Book CHS: What's New in This Year's Recommendations for the Diagnosis and Treatment of CLL?

Chronic lymphocytic leukemia (CLL) is the most common lymphoid malignancy in adults in Europe and…
7. 12. 2023 Source: Chronic Lymphocytic Leukemia

Articles on this topic
Pečovatel_senior

Older patients with CLL and comorbidities: an option for treatment with immunotherapy without chemotherapy?

Is it time to treat chronic lymphocytic leukemia (CLL) without chemotherapy? The authors of a…
19. 1. 2021 Source: Chronic Lymphocytic Leukemia
výzkum_laboratoř_experiment_medicína_zdravotnictví

Efficacy of Bruton Tyrosine Kinase Inhibitors After Venetoclax Therapy in Patients with CLL

Targeted therapy has changed the treatment approach for chronic lymphocytic leukemia (CLL),…
11. 12. 2020 Source: Chronic Lymphocytic Leukemia
Pacient_podpora

What Next for Patients with CLL After Stopping Venetoclax?

Standard care for untreated patients with chronic lymphocytic leukemia (CLL) is therapy based…
17. 7. 2020 Source: Chronic Lymphocytic Leukemia
Starší doktor u počítače vysvětluje mladé pacientce její zdravotní stav.

Temporary Interruption of Treatment or Dose Modification of Ibrutinib in CLL Patients

A team from the Mayo Clinic in Rochester, USA, published a study this March in the journal…
8. 6. 2020 Source: Chronic Lymphocytic Leukemia
pacient lékař konzultace prohlídka

Venetoclax in the Treatment of CLL: Open Doors for the Longest Possible Maintenance of Remission Without Active Therapy

William G. Wierda from MD Anderson Cancer Center in Houston, USA, and Francesco P. Tambaro…
8. 6. 2020 Source: Chronic Lymphocytic Leukemia
konference_kongres_přednáška_potlesk_medicína_lékaři

Role of Chemoimmunotherapy in the Era of Rapid Development of CLL Treatment Strategies and Emergence of New Drugs

In the context of the significant advancements in the field of immunotherapy and evidence of…
22. 4. 2020 Source: Chronic Lymphocytic Leukemia
konzultace - geriatrický pacient

Efficacy of Combination Therapy for Chronic Lymphocytic Leukemia in Patients with Complex Karyotype

A complex karyotype (presence of ≥ 3 chromosomal abnormalities) is a negative prognostic…
22. 4. 2020 Source: Chronic Lymphocytic Leukemia

New drugs in CLL may also carry specific risks of adverse effects. How to minimize and manage them?

The possibilities for the treatment of chronic lymphocytic leukemia (CLL) have greatly…
13. 3. 2020 Source: Chronic Lymphocytic Leukemia

Journal articles Encyclopedia of CLL Subsets –⁠ a Unique Bioinformatics Tool and Database for Analysis of Subsets of Stereotypical B-Cell Receptors in CLL

10. 4. 2019 Source: Clinical Oncology | Supplementum1/2019
patologie_laborator_nalez_histologie_rakovina_bunky

Journal articles Chronic lymphocytic leukaemia –⁠ contemporary application of modern prognostic and predictive markers  in diagnostics

29. 3. 2019 Source: Transfusion and Haematology Today | 1/2019
rodina_babicka_dcera

Journal articles Evolution of chronic lymphocytic leukemia treatment over the past 25 years

Nárůst poznatků o buněčné povaze, patogenezi a genetických změnách chronické lymfocytární leukemie...
29. 3. 2019 Source: Transfusion and Haematology Today | 1/2019

1 2
AbbVie logo 2025

Subscribe

E-courses on this topic

Course detail


Conferences news
PHD 2025: Jak chutná budoucnost hematoonkologie?

22. 1. 2025 - 24. 1. 2025
3 records Conference
Go to records
OHD 2023: Současné trendy v léčbě CLL a AML

26. 5. 2023 - 26. 5. 2023
3 records
Go to records
23. pražské hematologické dny - Satelitní sympozium společnosti Abbvie

18. 1. 2023 - 21. 1. 2023
1 record
Go to records
Z Olomouckých hematologických dnů: Zkušenosti s venetoklaxem v léčbě CLL

27. 5. 2022 - 27. 5. 2022
1 record
Go to records
Venetoklax v léčbě leukémie v roce 2022: Co je nového?

20. 1. 2022 - 21. 1. 2022
1 record
Go to records
ASH 2020: Výzkum v hematologii pokročil i v „době covidové“

7. 12. 2020 - 7. 12. 2020
1 record
Go to records
Novinky v léčbě CLL rezonovaly Pražskými hematologickými dny

22. 1. 2020 - 23. 1. 2020
1 record
Go to records

Most read on this topic
Journal on this topic
Related topic
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#